Who are Extended Phenytoin Sodium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Control (bupivacaine), Remifentanil+Lidocaine, Bupivacaine-fentanyl elective group, Exparel/bupivacaine mixture, ropivacaine and ketorolac, Propofol/Lidocaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/extended-phenytoin-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Extended Phenytoin Sodium — Competitive Intelligence Brief

Extended Phenytoin Sodium (Extended Phenytoin Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatic antiepileptic drug (hydantoin). Area: Neurology.

marketed Aromatic antiepileptic drug (hydantoin) Voltage-gated sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Extended Phenytoin Sodium (Extended Phenytoin Sodium) — Bristol-Myers Squibb. Extended-release phenytoin sodium blocks voltage-gated sodium channels in the brain to reduce neuronal excitability and prevent seizure propagation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Extended Phenytoin Sodium TARGET	Extended Phenytoin Sodium	Bristol-Myers Squibb	marketed	Aromatic antiepileptic drug (hydantoin)	Voltage-gated sodium channels
Control (bupivacaine)	Control (bupivacaine)	Kasr El Aini Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Propofol/Lidocaine	Propofol/Lidocaine	NYU Langone Health	marketed	Intravenous anesthetic combination	GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatic antiepileptic drug (hydantoin) class)

Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Extended Phenytoin Sodium — Competitive Intelligence Brief. https://druglandscape.com/ci/extended-phenytoin-sodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab